Abbott’s board of directors increased the company’s quarterly common dividend, marking a 50th consecutive year of dividend growth.
GlaxoSmithKline will lay out plans to boost the spending power of the company’s research-focused pharmaceuticals business at an investor day on June 23, as analysts call on the British drugmaker to boost drug development prospects with takeovers or alliances.